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Sir,
Since 1989, plasmid-mediated AmpC b-lactamases have been
known to exist in various species lacking inducible chromoso-
mal ampC genes such as Klebsiella spp., Escherichia coli,
Proteus mirabilis and Salmonella. They descend from chromo-
somal ampC genes and fall into six phylogenetic groups.
Origins are the ampC genes of Hafnia alvei, Morganella morga-
nii, Citrobacter freundii, Enterobacter cloacae and two
unknown organisms.1 Organisms producing plasmid-mediated
AmpC b-lactamases raise special concerns because of the high
rate of clinical failure among infected patients.2 We report here
on the prevalence of plasmid-mediated AmpC b-lactamases in
isolates of Enterobacteriaceae lacking an inducible chromosomal
ampC gene at University Hospital Basel and the occurrence
of different molecular types of plasmid-mediated AmpC b-
lactamases in Switzerland.
Between 27 January 2006 and 27 January 2007, a total of 3217
consecutive clinical isolates of various species of
Enterobacteriaceae lacking inducible chromosomal ampC genes
(i.e. 2434 E. coli, 174 Klebsiella oxytoca, 459 Klebsiella pneumo-
niae, 8 Klebsiella spp., 134 P. mirabilis, 7 Salmonella enterica
ssp. enterica and 1 Shigella flexneri) were screened for resistance
to cefoxitin with the disc diffusion test according to CLSI guide-
lines.3 Isolates with an inhibition zone diameter of ,18 mm were
considered putative AmpC producers and were stored at 2708C
for further investigation. Additionally, 45 clinical isolates sus-
pected to harbour a plasmid-mediated AmpC b-lactamase were
collected from 5 laboratories situated in Switzerland. ampC genes
were identified by a ampC multiplex PCR with primers specific
for the genes of six different phylogenetic groups.1 For sequen-
cing, the ampC genes were amplified by PCR using primer pairs
as described previously for blaCMY and blaDHA, respectively.
4,5 In
addition, blaCMY-31 was amplified using a second pair of primers.
6
PCR products were purified using Montage PCR Units (Millipore,
Zug, Switzerland) and sequencing reactions were carried out using
a BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Rotkreuz, Switzerland) as described by the manufac-
turer. Sequencing products were purified with Dye Ex 2.0 Spin Kit
(Qiagen, Hombrechtikon, Switzerland) and electrophoresis was
performed with the 3130 Genetic Analyzer (Applied Biosystems).
The isoelectric point (pI) of the new b-lactamase was determined
by isoelectric focusing, applying the supernatants of crude sonic
cell extracts to Phast gels (GE HealthCare, Fairfield, CT, USA)
with a pH gradient of 3–9 in a Phast system (GE HealthCare).
Extended-spectrum b-lactamases (ESBLs) with known pI values
(TEM-1, TEM-12, SHV-12 and CTX-M15) were included as
pI markers. A filter paper containing 2.5% flucloxacillin
(GlaxoSmithKline, Munchenbuchsee, Switzerland) as an inhibitor
of the AmpC b-lactamase was applied for 2 min to one of the gels
before staining with nitrocefin (Oxoid, Basel, Switzerland).
Of 3217 consecutive clinical isolates that were obtained at our
hospital, 124 (3.8%; 103 E. coli, 3 K. oxytoca and 18
K. pneumoniae) were resistant to cefoxitin and were thus con-
sidered putative AmpC producers. Among these, five isolates (all
of them E. coli) carrying an ampC gene known to be
plasmid-encoded were found by ampC multiplex PCR. Thus,
the prevalence of plasmid-mediated AmpC b-lactamases at
University Hospital Basel was 0.16% for Enterobacteriaceae
lacking an inducible chromosomal ampC gene (0.2% for E. coli).
Overall, plasmid-mediated AmpC b-lactamases were found
in 17 isolates obtained from five Swiss laboratories. Details are
given in Table 1. Fourteen of the isolates were E. coli, two
were K. pneumoniae and one was P. mirabilis. Fifteen of the
plasmid-mediated AmpC b-lactamases were CIT enzymes, a
phylogenetic group that has its origin in the chromosomal
ampC gene of C. freundii. Fourteen of them were CMY-2. For
one isolate of K. pneumoniae, sequencing of the full gene
revealed a unique sequence that has been designated CMY-31
(GenBank accession no. EF622224). The derived amino acid
sequence differed from CMY-2 by one amino acid (Q235R).
Isoelectric focusing revealed a b-lactamase with a pI between
8.8 and 9.0. Enzyme activity of CMY-31 was inhibited by flu-
cloxacillin which is indicative of an AmpC b-lactamase.
Enzyme activity of the ESBLs that served as pI markers was
retained. This is the first report of the isolation and character-
ization of CMY-31, a new b-lactamase which is closely
related to CMY-2. DHA-1, a plasmid-mediated AmpC
b-lactamase that has its origin in the chromosomal ampC gene
Table 1. Occurrence of various molecular types of AmpC
Molecular type of AmpC Number of isolates Species
CMY-2 12 E. coli
CMY-2 1 K. pneumoniae
CMY-2 1 P. mirabilis
DHA-1 2 E. coli
CMY-31 1 K. pneumoniae
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of M. morganii, was detected in two isolates of E. coli.
DHA-1 is an inducible plasmid-mediated AmpC b-lactamase
whose emergence raises concerns because the mortality of
patients infected with organisms that produce DHA-1 has been
shown to be higher than that of patients infected with organ-
isms that produce CMY-1.2
In conclusion, we have demonstrated that plasmid-mediated
AmpC b-lactamases have emerged in Switzerland. The preva-
lence of 0.16% is still low. However, the occurrence of DHA-1,
an inducible type of enzyme, raises clinical concerns.
Additionally, a novel plasmid-mediated AmpC b-lactamase,
which was designated CMY-31, was found.
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Sir,
Resistance to macrolide, lincosamide and streptogramin B
(MLSB) antibiotics in Staphylococcus spp. is mediated by a
methylase encoded by erythromycin ribosome methylation (erm)
genes or ATP transporter efflux pumps encoded by the msr or
mef genes. The methylation of the 50S ribosomal subunit by
erm gene products causes constitutive or inducible resistance to
MLSB antibiotics. Constitutively resistant MLSB (MLSBc)
strains and inducibly resistant MLSB (MLSBi) strains express
erm genes, erm(A) or/and erm(C). In this study, we investigated
and characterized the constitutive and inducible resistance, and
the susceptibility to clindamycin of Staphylococcus aureus iso-
lated from non-tertiary hospitals.
We collected 508 S. aureus strains from 157 hospitals nation-
wide from January to June 2005 in Korea. Antimicrobial suscep-
tibility to oxacillin, erythromycin, clindamycin and quinupristin/
dalfopristin and the MICs were evaluated according to the
guidelines of the CLSI. Of the 508 S. aureus isolates, 46.1%
(234 isolates) were resistant to oxacillin, 55.1% (280 isolates) were
resistant to erythromycin, which comprised 98.3% (230/234)
methicillin-resistant S. aureus (MRSA) strains and 18.2%
(50/274) methicillin-susceptible S. aureus (MSSA) strains, and
37.4% (190 isolates) were resistant to clindamycin. No strains
were susceptible to erythromycin and resistant to clindamycin.
One hundred and eighty-six MRSA (80.9%) and four MSSA
(8.0%) were MLSBc (resistant to erythromycin and clindamycin;
Table 1). D-test according to Steward’s method was used for iso-
lates with erythromycin resistance and clindamycin susceptibility.1
Forty-three MRSA (18.7%) and 40 MSSA (80.0%) were MLSBi
(showing the D form on the D-test), and 1 MRSA (0.4%) and 6
MSSA (12.0%) were MLSBs (susceptible to clindamycin).
The MLSB resistance genes, erm(A), erm(B), erm(C),
msr(A), msr(B) and mef, were detected using a PCR method.2
erm(A) was detected in 250 strains, erm(C) in 14 strains, erm(B)
in 1 strain, msr(A) in 3 strains, erm(A) and erm(C) in 2 strains,
erm(A) and msr(A) in 3 strains and no genes in 7 strains.
Most MLSBc and MLSBi strains carried the erm(A) or
erm(C) gene (Table 1). The erm(A) gene (in 250 isolates) was
detected far more frequently than erm(C) (in 14 strains).
However, the erm(C) gene was distributed more frequently in
MLSBi strains (12 isolates) than in MLSBc strains (2 isolates).
Using OLIGO primers designed by Arthur et al.,3 the PCR pro-
ducts were detected in three MLSBc or MLSBi strains lacking
erm(A), erm(B) or erm(C). It was possible that the three strains
carry an erm gene besides erm(A), erm(B) or erm(C). msr(A)
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